Israeli Biotech Firm Trying To Print Organs For Transplants
Image by iStock
Israeli biotech firm CollPlant is trying to patent a technology that that could eventually lead to the three-dimensional printing of hearts, kidneys and other vital human tissues.
CollPlant, based in Ness Ziona, has filed a patent application in the United States for its “bio-ink” – made of a proprietary plant product that mimics the qualities of collagen, a protein responsible for the elasticity of human skin and other organs.
Combined with other hormones and existing human cells, the bio-ink could eventually be used to create organs for those in need – easing pressure on the transplant process, which for the most part relies on harvested organs from the deceased.
“We are promoting commercial collaborations with leading international companies in the field of 3D bio-printing of tissue and organ, with the aim of taking part in providing a solution to the significant need for life saving organs,” Yehiel Tal, CEO of CollPlant, told the Jerusalem Post.
Contact Daniel J. Solomon at [email protected] or on Twitter @DanielJSolomon
The Forward is free to read, but it isn’t free to produce
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward.
Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.
At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse.
This is a great time to support independent Jewish journalism you rely on. Make a gift today!
— Rachel Fishman Feddersen, Publisher and CEO
Support our mission to tell the Jewish story fully and fairly.
Dive In
-
Fast Forward Trump administration restores student visas, but impact on pro-Palestinian protesters is unclear
-
Fast Forward Deborah Lipstadt says Trump’s campus antisemitism crackdown has ‘gone way too far’
-
Fast Forward 5 Jewish senators accuse Trump of using antisemitism as ‘guise’ to attack universities
-
Fast Forward Jewish Democratic Rep. Jan Schakowsky reportedly to retire after 26 years in office
Most Popular
- 1
Opinion The dangerous Nazi legend behind Trump’s ruthless grab for power
- 2
Opinion A Holocaust perpetrator was just celebrated on US soil. I think I know why no one objected.
- 3
Culture Did this Jewish literary titan have the right idea about Harry Potter and J.K. Rowling after all?
- 4
Opinion I first met Netanyahu in 1988. Here’s how he became the most destructive leader in Israel’s history.
In Case You Missed It
-
Opinion Gaza and Trump have left the Jewish community at war with itself — and me with a bad case of alienation
-
Fast Forward Trump administration restores student visas, but impact on pro-Palestinian protesters is unclear
-
Fast Forward Deborah Lipstadt says Trump’s campus antisemitism crackdown has ‘gone way too far’
-
Fast Forward 5 Jewish senators accuse Trump of using antisemitism as ‘guise’ to attack universities
-
Shop the Forward Store
100% of profits support our journalism
Republish This Story
Please read before republishing
We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines.
You must comply with the following:
- Credit the Forward
- Retain our pixel
- Preserve our canonical link in Google search
- Add a noindex tag in Google search
See our full guidelines for more information, and this guide for detail about canonical URLs.
To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.